10.30am – 12.05pm GMT, 19 December 2024 ‐ 1 hour 35 mins
Podium Lecture
10-30 Ethics - Tacey Kobayashi
10-37 Safety - Justin Green
10:45 Bias: PROBAST & CHARMS… what do we mean? - Luke Farrow
10:53 Model Selection …. What do we mean? - Peter Harris
11:03 Hardware, Virtualization, Deployment and Monitoring - Chris Tromans
11:11 Where Data Engineers fit in - Cheuk Ting.Ho
11:19 Data security and federated technology….. what do we mean? - Luke Farrow
11:29 Digital technology deployment – one size does not fit all! - Philip Breedon
11-39 Maximising the success of your innovation! - James Naylor
Consultant Orthopaedic Surgeon, South West London Elective Orthopaedic Centre (SWLEOC)
Dr. Xiatian Zhu is a Senior Lecturer at the Surrey Institute of People-Centred AI and the Centre for Vision, Speech, and Signal Processing (CVSSP) at the University of Surrey in Guildford, UK. He leads the Universal Perception (UP) lab, which focuses on advancing multimodal generative AI for real-world applications and business.
Dr. Zhu earned his PhD from Queen Mary University of London and received the 2016 Sullivan Doctoral Thesis Prize from the British Machine Vision Association, an honour recognizing excellence in AI technologies within computer vision. His contributions include the development and commercialization of multi-camera object association systems for industry. During his time as a research scientist at the Samsung AI Centre in Cambridge, Dr. Zhu pioneered sustainable AI algorithms for understanding visual content in images and videos. His work has garnered several best paper awards, and he has been recognized as one of the UK's and the world's best rising stars in science. Dr. Zhu's extensive research output includes over 150 articles in top-tier international conferences and journals, with more than 18,000 citations and an H-index of 54. He actively contributes to the academic community through workshop organization, serving as a senior program committee member and area chair, and participating in panel debates on emerging trends in AI. Additionally, Dr. Zhu holds five US patents in the fields of AI and computer vision.
Tacey Kobayashi has been analysing data for more than 20 years for the Civil Service and the Wellcome Trust, moving from policy analysis to data science using Python creating customer profiles from hard drives, analysing online library search terms, researcher behaviour with force-directed graphs and using tensors for computer vision models.
Peter Harris is the Director of Research Science at NielsenIQ, where he leads a global team of Artificial Intelligence researchers. NielsenIQ is a multinational company dedicated to understanding consumer behaviour worldwide. In addition to his role at NielsenIQ, Peter serves as an AI consultant for the NHS, leveraging advanced AI techniques to predict medical conditions from x-rays before they are visible to the human eye. His expertise spans several cutting-edge domains, including Natural Language Processing, Image Classification, Graph Neural Networks, and Generative AI (in collaboration with Microsoft).
After having a career as a Data Scientist and Developer Advocate, Cheuk dedicated her work to the open-source community. Currently, she is working as AI developer advocate for JetBrains. She has co-founded Humble Data, a beginner Python workshop that has been happening around the world. She has served the EuroPython Society board for two years and is now a fellow and director of the Python Software Foundation.
James Naylor is a Senior Marketing Manager for Johnson & Johnson MedTech and works across digital technology and Hips. James has been in Orthopaedics as part of Sales or Marketing for more than 20 years starting as a sales rep and moving through to his current role as a Strategic Marketer for the Global Group. In his current role James is responsible for the management and delivery of digital projects within Hips and owns the future roadmaps for digital technology Globally for Hips. James’ role involves sourcing companies and products that fit the roadmaps and onboarding those companies as valued partners.